2664
CAWACHI LIMITED
カワチ薬品
- Industry
- Retail Trade
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
284,492
Mar 2022
279,462
Mar 2023
281,871
Mar 2024
285,960
Mar 2025
287,816
Operating profit(million JPY)
Mar 2021
10,560
Mar 2022
7,709
Mar 2023
6,611
Mar 2024
7,601
Mar 2025
7,461
Operating profit margin(%)
Mar 2021
3.71
Mar 2022
2.76
Mar 2023
2.35
Mar 2024
2.66
Mar 2025
2.59
Profit before tax(million JPY)
Mar 2021
10,636
Mar 2022
7,687
Mar 2023
6,572
Mar 2024
7,153
Mar 2025
6,827
Profit(million JPY)
Mar 2021
7,109
Mar 2022
4,830
Mar 2023
4,177
Mar 2024
4,713
Mar 2025
4,884
Total assets(million JPY)
Mar 2021
194,100
Mar 2022
191,721
Mar 2023
194,496
Mar 2024
196,119
Mar 2025
199,601
Cash and cash equivalents(million JPY)
Mar 2021
41,235
Mar 2022
38,959
Mar 2023
38,450
Mar 2024
35,623
Mar 2025
36,674
Cash flows from operating activities(million JPY)
Mar 2021
15,267
Mar 2022
6,868
Mar 2023
9,817
Mar 2024
6,402
Mar 2025
7,481
Cash flows from investing activities(million JPY)
Mar 2021
-3,152
Mar 2022
-4,536
Mar 2023
-5,840
Mar 2024
-5,291
Mar 2025
-4,515
Cash flows from financing activities(million JPY)
Mar 2021
-3,984
Mar 2022
-4,607
Mar 2023
-4,485
Mar 2024
-3,937
Mar 2025
-1,915
Return on equity(%)
Mar 2021
7.3
Mar 2022
4.7
Mar 2023
3.9
Mar 2024
4.3
Mar 2025
4.3
Equity ratio(%)
Mar 2021
51.9
Mar 2022
54.5
Mar 2023
55.3
Mar 2024
56.7
Mar 2025
57.3
Earnings per share(JPY per share)
Mar 2021
318.73
Mar 2022
216.44
Mar 2023
187.06
Mar 2024
211.03
Mar 2025
218.72
Net assets per share(JPY per share)
Mar 2021
4,517.46
Mar 2022
4,682.61
Mar 2023
4,818.93
Mar 2024
4,980.82
Mar 2025
5,120.32
Dividend per share(JPY per share)
Mar 2021
50
Mar 2022
50
Mar 2023
50
Mar 2024
80
Mar 2025
80
Payout ratio(%)
Mar 2021
15.69
Mar 2022
23.1
Mar 2023
26.73
Mar 2024
37.91
Mar 2025
36.58
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.